Mark A. Lemmon

2000 -

photo credits: Wikimedia Commons

country of citizenship: United Kingdom

languages spoken, written or signed: English

educated at: Yale University, Norwich School, Hertford College

occupation: researcher, biochemist

award received: Fellow of the Royal Society

Mark Andrew Lemmon (born 1964) an English-born biochemist, is the Alfred Gilman Professor and Department Chair of Pharmacology at Yale University where he also directs the Cancer Biology Institute. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 154

Date

Title

Authors

2022-10-15

Looking lively: emerging principles of pseudokinase signaling

Joshua B Sheetz, Mark A. Lemmon
2022-02

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Chun Hu, Anatoly Kiyatkin, Mark A. Lemmon
2022-11-10

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Mark A. Lemmon
2021-01-28

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

Adam J Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Gwenn M Hansen, Stefan Knapp, John M Maris, Ronen Marmorstein, Linda Z Penn, Kevan M. Shokat, Kliment A Verba, William A Weiss, Elmar Wolf, Mark A. Lemmon
2021-11-24

Structural basis for ligand reception by anaplastic lymphoma kinase

Mark A. Lemmon
2021-10-19

ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes

Joshua B Sheetz, Kay Perry, Zhong-Yuan Kan, Mark A. Lemmon
2021-09-14

Phosphatidylserine binding directly regulates TIM-3 function

Mark A. Lemmon
2021-03-09

Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation

Ravi Radhakrishnan, Mark A. Lemmon
2020-03-19

Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations

Kamrine E Poels, Robert J. Homer, Mark A. Lemmon, Franziska Michor
2020-04-16

Insulin and EGF receptor family members share parallel activation mechanisms

Mark A. Lemmon, Chun Hu
2020-06-24

Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases

Robert Perttilä, Sebastian Mathea, Ketan Malhotra, Joshua B Sheetz, Hanna Karvonen, Daniela Ungureanu, Mark A. Lemmon, Stefan Knapp
2020-08-18

Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics

Anatoly Kiyatkin, Mark A. Lemmon
2020-10-12

Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB

Mark A. Lemmon
2019-01-01

Non-acylated Wnts Can Promote Signaling

Mark A. Lemmon, Benjamin Tajer, Kelsey Speer
2019-08-06

Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma

Marta Baro, Mark A. Lemmon, Barbara Burtness
2019-06-10

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Mark A. Lemmon, Anna Wurtz, Daniel Zelterman
2019-04-13

Computational algorithms for in silico profiling of activating mutations in cancer

Mark A. Lemmon, Ravi Radhakrishnan
2018-01-17

Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.

Mark A. Lemmon, Jan Steyaert, Joseph Schlessinger, Sangwon Lee, Els Pardon
2018-01-17

Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23.

Mark A. Lemmon, Nicole Frazier, Ketan Malhotra, Daniel M. Freed
2018-10-01

Smoothening out the patches

Mark A. Lemmon
2018-10-01

Flipping ATP to AMPlify Kinase Functions

Mark A. Lemmon, Joshua B Sheetz
2018-06-28

Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain

Mark A. Lemmon
2017-10-04

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Daniel M. Freed, Mark A. Lemmon, Diane S. Lidke, Anatoly Kiyatkin
2017-04-10

Dimerization of Tie2 mediated by its membrane-proximal FNIII domains

Mark A. Lemmon
2016-04-01

Deletion Mutations Keep Kinase Inhibitors in the Loop

Daniel M. Freed, Mark A. Lemmon
2016-01

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Mark A. Lemmon
2016-03-01

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators

Mark A. Lemmon, Daniel M. Freed, Anatoly Kiyatkin, Joseph Schlessinger
2016-11-22

Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase

Mark A. Lemmon
2016-09-05

Overcoming resistance to HER2 inhibitors through state-specific kinase binding

Mark A. Lemmon, Weijun Shen
2015-06-04

EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features

Mark A. Lemmon, Michael Simpson, John Mcgrath, Rebecca D Ganetzky, Neal Sondheimer
2015-01-22

Comparison of Saccharomyces cerevisiae F-BAR domain structures reveals a conserved inositol phosphate binding site

Mark A. Lemmon
2015-06-10

Ligand regulation of a constitutively dimeric EGF receptor

Mark A. Lemmon, Daniel M. Freed

Human - wd:Q24076870

Welcome to Inventaire

the library of your friends and communities

learn more